http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Chemomab+Therapeutics++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./26779679.html si-local-file:///var/storage/secattach/20260716/26779679.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Chemomab+Therapeutics++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./26779679.html Thu, 16 Jul 2026 16:06:00 -0400 CMMB O.13812250 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Chemomab+Therapeutics++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./26779679.html si-local-file:///var/storage/secattach/20260716/26779679.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Chemomab+Therapeutics++++++++++++++++++Filed+by%3A+HBM+Healthcare+Investments+%28Cayman%29+Ltd./26779679.html Thu, 16 Jul 2026 16:06:00 -0400 CMMB O.13812250 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html <p>Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine Corporation have entered into a definitive merger agreement to combine in a stock transaction, the companies announced July 8, 2026.</p> <p>Under the terms of the agreement, the combined company will operate as Scipher Medicine Corporation and is expected to trade on Nasdaq under the ticker symbol "SCIP." Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%, each on a fully diluted basis.</p> <p>The combined company is valued at $150 million before a concurrent $30 million private placement led by http://www.streetinsider.com/FDA/Chemomab+and+Scipher+Medicine+agree+to+merge+in+%24150M+deal/26744279.html Wed, 08 Jul 2026 07:36:15 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Press+Releases/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496 http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html <p align="center"><em>Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success </em></p> <p align="center"><em>Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug</em></p> <p align="center"><em>Phase 2 RA clinical study expected to read out in H1 2028, providing http://www.streetinsider.com/Globe+Newswire/Chemomab+Therapeutics+and+Precision+Medicine+Pioneer+Scipher+Medicine+Announce+Merger+Agreement+to+Advance+Nebokitug+in+an+AI-Powered+Phase+2+Trial+in+Rheumatoid+Arthritis/26744278.html Wed, 08 Jul 2026 07:35:00 -0400 A.10710336 A.28005717 A.50216997 CMMB O.02826370 O.13812250 O.20020231 O.38759496